Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 27th March 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 1, 2019
Previous Article Next Article

Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches

Author affiliations

Abstract

Neuropsychiatric disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD) and depression, have seriously inconvenienced the lives of patients. Growing evidence indicates that these diseases are closely related to the monoamine oxidase (MAO) enzyme, making it an attractive target for the exploitation of potent MAO inhibitors (MAOIs) with high selectivity and low side effects. Although various MAOIs have been discovered, the discovery of an ideal MAOI is not an easy task. In this review, we discuss the currently available rational design strategies for obtaining ideal MAOIs, including ligand-based and receptor-based design strategies, and these strategies were further illustrated with the aid of specific examples from the recent literature. To better understanding the biological activity of MAO, we also highlight the binding modes of typical inhibitors against MAO. Besides, advanced strategies for finding upcoming potent MAOIs were prospected.

Graphical abstract: Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches

Back to tab navigation

Publication details

The article was received on 05 Sep 2018, accepted on 22 Nov 2018 and first published on 24 Nov 2018


Article type: Review Article
DOI: 10.1039/C8MD00446C
Citation: Med. Chem. Commun., 2019,10, 10-25

  •   Request permissions

    Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches

    R. Hong and X. Li, Med. Chem. Commun., 2019, 10, 10
    DOI: 10.1039/C8MD00446C

Search articles by author

Spotlight

Advertisements